Last Updated:
This effort by Neuralink is an important step in brain-computer interface technology, which may open new possibilities for the treatment of serious neurological conditions in the future.
New Delhi. Elon Musk’s company Neuralink Corp has successfully implanted its brain-computer device in the brain of a third patient. Earlier Neuralink had successfully implanted computer chips in the brains of two people and now once again the company has been successful in doing so. Elon Musk himself gave this information in an event organized in Las Vegas. Musk said that there is a plan to implant chips in the brains of 20 to 30 humans in 2025.
Neuralink is one of the startups that are developing brain implants that can help in the treatment of diseases like paralysis and ALS. A year ago, Neuralink implanted this device in the brain of its first patient, Noland Arbaugh. In September 2023, Musk’s brain-chip company Neuralink received recruitment approval from the Independent Institutional Review Board for its first human trial.
Smartphone will be controlled by brain
Elon Musk said on the third trial of Neuralink, “We have so far implanted Neuralink in the brains of three humans, and all of them are working well.” It is noteworthy that the company has registered two studies for its device with the Food and Drug Administration (FDA) in America. The first of these, the Prime study, is designed for five patients, allowing paralyzed patients to control external devices such as computers or smartphones with their brain. The second study, Convoy, is for three patients, in which they can control devices such as assistive robotic arms.
This effort by Neuralink is an important step in brain-computer interface technology, which may open new possibilities for the treatment of serious neurological conditions in the future. If the human trial is successful then blind people will be able to see through the chip. Paralysis patients will be able to walk and also operate computers. The company has named this chip ‘Link’.
The trial is being conducted on people who have quadriplegia due to cervical spinal cord injury or amyotrophic lateral sclerosis (ALS). The age of the participants in this trial should be minimum 22 years. The study will take about 6 years to complete. During this time, the company also provides travel expenses to the participant to and from the lab.
